Colistin-Resistant Acinetobacter baumannii Isolated from Ventilator-Associated Pneumonia: A Case Report from Turkey

Ventilatör-İlişkili Pnömoniden İzole Edilen Kolistin Dirençli Acinetobacter baumannii: Türkiye’den Bir Olgu Sunumu

Gülbin AYGENCEL1, Murat DİZBAY2, Arzu ÇİFTÇİ2, Melda TÜRKOĞLU1

1 Gazi Üniversitesi Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Yoğun Bakım Bilim Dalı, Ankara, Türkiye
Division of Intensive Care, Department of Internal Medicine, Faculty of Medicine, University of Gazi, Ankara, Turkey

2 Gazi Üniversitesi Tıp Fakültesi,İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı, Ankara, Türkiye
Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, University of Gazi, Ankara, Turkey

ABSTRACT

Multidrug-resistant Acinetobacter baumannii is one of the most important pathogens in intensive care units related to morbidity and mortality. Colistin is being used increasingly as “salvage” therapy for these patients. However, resistance to colistin in A. baumannii has recently been reported. We herein present a case in which ventilator-associated pneumonia due to A. baumannii developed in one of our patients in the intensive care unit. Colistin was initiated in the patient; however, resistance was observed during the treatment. Our aim in presenting this case is to attract attention to the potential risks of multidrug-resistant Acinetobacter infections in Turkey.

Key Words: Acinetobacter baumannii, Ventilator-associated pneumonia, Colistin, Resistance.

Received: 01/02/2010 • Accepted: 14/10/2010

ÖZET


Anahtar Kelimeler: Acinetobacter baumannii, Ventilatör ilişkili pnömoni, Kolistin, Direnç

Geliş Tarihi: 01/02/2010 • Kabul Edilish Tarihi: 14/10/2010
INTRODUCTION

Acinetobacter species have increasingly been recognized as hospital-acquired pathogens mainly in immunocompromised patients and patients in intensive care units (ICUs) (1). Acinetobacter spp. can cause a multitude of infections, including pneumonia, bacteremia, meningitis, urinary tract infections, and skin and soft tissue infections, and mortality rates associated with these infections are quite high. Emergence of pan-drug-resistant (PDR) or multidrug-resistant (MDR) A. baumannii strains has become a serious clinical problem in many parts of the world (2). Antimicrobial options for the treatment of MDR A. baumannii are limited, including polymyxins (e.g. colistin), unusual drugs (e.g. sulbactam) or drugs with which there is presently little clinical experience (e.g. tigecycline). Colistin is being used increasingly as salvage therapy for this pathogen (3). Unfortunately, resistance to colistin has emerged with its increasing use, and there is a recent observation of heteroresistance to colistin among clinical strains of MDR A. baumannii (4).

In this study, we present a patient who developed ventilator-associated pneumonia (VAP) due to A. baumannii in our ICU, for which colistin treatment was initiated; however, resistance was observed during treatment. In view of this case, we would like to emphasize the likelihood of colistin resistance in Acinetobacter infections.

CASE REPORT

An 82-year-old female patient with a history of atrial fibrillation and who used warfarin (Coumadin®) due to a cerebrovascular event presented to the emergency service of Gazi University Hospital with a complaint of gastrointestinal bleeding. Having performed replacement and endoscopy, she was hospitalized in the internal medicine clinic for follow-up. On the fifth day of her admission, she arrested, was intubated, and was transferred to our ICU for further follow-up and treatment. On her initial endotracheal aspirate (ETA) culture, methicillin-resistant Staphylococcus aureus (MRSA) was isolated and linezolid treatment was started. On her fifth day of intubation, she was extubated. The patient was then transferred back to the internal medicine clinic; however, on the fourth day of her observation in the clinic, she developed acute respiratory failure. Therefore, she was intubated and re-admitted to the ICU. On the second day of her admission in the ICU, A. baumannii (ETA: 3 x 10^5 colony, susceptible to only colistin and netilmicin, mean inhibitory concentration (MIC): 0.5 µg/mL for CT) was isolated in the ETA culture. The patient then received colistin (intravenous and inhalation route). On the seventh day of her admission, she was again extubated, but this time her extubation period lasted for five days. Due to her increasing secretion and respiratory problems, she had to be intubated a third time. Following the third intubation, a tracheostomy was performed and she was assessed with regard to her daily weaning trial, but the patient could not be totally withdrawn from the mechanical ventilation. On the 15th day of her admission to the ICU, she developed fever again, and on the ETA culture, A. baumannii (ETA: 7 x 10^4 colony, susceptible only to NET, MIC: > 32 µg/mL for CT) was isolated once again. Therefore, netilmicine and rifampin were administered; however, on the 21st day of her admission in the ICU, the patient died due to sepsis and septic shock.

Isolates were collected from ETA cultures from the patient. A. baumannii isolates growing on ETA cultures were tested for antimicrobial susceptibility by disk diffusion method. Isolates resistant to at least three different antibiotics, including carbapenems, aminoglycosides, quinolones, piperacillin/tazobactam, cefepime, ceftazidime, and cefoperazone/sulbactam, were considered as MDR A. baumannii. A. baumannii strains from VAP were identified using a BBL Crystal Enteric/Nonfermenter ID Kit (Becton Dickinson, Sparks, MD).

The in vitro antimicrobial susceptibility for colistin was also confirmed by Etest (AB BIODISK, Solna, Sweden). Large (150 mm) agar plates with Mueller-Hinton medium (Becton Dickinson) were inoculated with suspensions of the strains equivalent to 0.5 McFarland standard, and Etest strip of colistin was applied. After incubation for 24 hours at 35°C, MICs were read and interpreted according
to the manufacturer’s instructions and Clinical and Laboratory Standards Institute (CLSI 2008) recommendations. According to CLSI 2008 recommendations, colistin susceptibility criterion for *A. baumannii* is MIC ≤ 2 µg/mL and resistance criterion is MIC ≥ 4 µg/mL (5).

**DISCUSSION**

In the last two decades, *A. baumannii* has become an important nosocomial pathogen in Turkey as well as throughout the world and is a leading problem in treatment due to its MDR (6). Carbapenems, quinolones, aminoglycosides, and combinations with sulbactam are commonly used in the treatment of these infections. Unfortunately, resistance rates for these antibiotics are increasing. In various studies performed in ICUs from Turkey, carbapenem resistance in *A. baumannii* was reported to be between 55% and 63% (6-8).

Increasing carbapenem resistance due to OXA-type carbapenemase or, more rarely, metallo-beta-lactamases, among *A. baumannii* isolates has led clinicians to look for new therapeutic alternatives. Many carbapenemase-producing *A. baumannii* isolates are resistant to all available agents except polymyxins (9,10). Tigecycline, which is active against most carbapenemase-producing strains, may be a useful alternative to polymyxins. Tigecycline, a new semi-synthetic tetracycline, has provided hope for the treatment of *A. baumannii* infections, including carbapenem-resistant isolates. However, *A. baumannii* isolates showing reduced susceptibility to tigecycline have recently been identified (6,11,12). Furthermore, tigecycline was not approved for the treatment of VAP, so there is presently little clinical experience with this drug.

Colistin, an old antibiotic from the polymyxin group, is very effective against MDR *A. baumannii* isolates, but the emergence of resistance has occasionally been experienced. Moreover, unfavorable pharmacokinetic properties and possible adverse effects (e.g. nephrotoxicity and neurotoxicity) restrict its clinical use (4,13). In addition, colistin is not available in Turkey and can only be obtained abroad.

Colistin is one agent reliably active against many *Acinetobacter* isolates. Heteroresistance to colistin among *Acinetobacter* isolates has been previously described in some reports, and preliminary in vitro data indicate that the emergence of heteroresistant populations may be amplified by colistin exposure. In other words, it is possible that the heteroresistant proportion of the bacterial population might be selected and become predominant during colistin therapy, leading to treatment failure. Monotherapy with colistin has been described as a risk factor for the selection of heteroresistant isolates. Careful monitoring for emerging resistance during prolonged colistin therapy is warranted (14,15).

Heteroresistance to colistin in clinical isolates of *A. baumannii* that are apparently susceptible to colistin is considered on the basis of MICs. The detection of hetero-colistin-resistant *A. baumannii* in the clinical isolates provides a strong warning that if colistin is used inappropriately, there may be substantial potential for the rapid development of resistance and therapeutic failure. Monotherapy with colistin for treatment of infections caused by hetero-colistin-resistant *A. baumannii* may be problematic. We believe that resistance to this last-resort antibiotic should be monitored in global and local surveillance programs and that every effort should be made to increase its life span by ensuring that it is used judiciously and in appropriate dosage regimens (15-17).

Hernan et al. showed the high presence of colistin heteroresistant strains with endemic infections in an ICU (18). Thus, combination therapy has become the ultimate resource to treat MDR and PDR *A. baumannii* infections, but its actual efficacy is unclear from a microbiological and clinical viewpoint (19).

In our case, VAP due to *A. baumanii* developed in the patient on her admission to the ICU, and colistin, to which her isolate was sensitive, was administered initially as a monotherapy. During administration of colistin, the study conducted by Dizbay et al. in our hospital in 2008 (in which colistin resistance was found as 0% and tigecycline resistance as 25.8%) and the MIC value for colistin were taken into consideration (6). However, as also indicated in other similar previous studies, resistance under colistin monotherapy developed in our patient. Since the infection could not be cont-
rolled, she died due to sepsis. This case rekindled our interest in the fact that *Acinetobacter* infections can also lead to major problems in Turkey, as have been experienced worldwide, due to this existing and rapidly spreading resistance problem in the treatment.

**CONCLUSION**

*A. baumannii* has emerged recently as an important pathogen frequently isolated from VAP worldwide. MDR *A. baumannii*-related infections and outbreaks have become a health problem in many countries as well as in Turkey.

There is no simple answer to the treatment of *Acinetobacter* infections. A high prevalence of MDR in *A. baumannii* limits the therapeutic options in the treatment. Eradication of *Acinetobacter* spp. requires adherence to good infection control practices and prudent antibiotic use, as well as effective antimicrobial therapy. Although colistin appears to be a good choice, adverse reactions and unavailability of colistin limit its wide usage in Turkey. Moreover, potential risk of resistance limits its usage worldwide.

**REFERENCES**


**Yazışma Adresi/Address for Correspondence**

Doç. Dr. Gülbin AYGENCEL
Gazi Üniversitesi Tıp Fakültesi
İç Hastalıkları Anabilim Dalı
İç Hastalıkları Anabilim Dalı 06510
Beşevler, Ankara-Türkiye
E-posta: aygencel@hotmail.com